Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 195

Results For "Pharma"

3788 News Found

Remedium Lifecare to acquire manufacturing facility in Hyderabad
News | March 08, 2024

Remedium Lifecare to acquire manufacturing facility in Hyderabad

The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes


Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh
Biotech | March 07, 2024

Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh

India has reached to nearly 6,000 bio-startups from 50 in the past 10 years


Venus Remedies awarded its first incentive of Rs.7.50 crore under PLl scheme
Policy | March 07, 2024

Venus Remedies awarded its first incentive of Rs.7.50 crore under PLl scheme

The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics


Govt supports Alchem Synthon with Rs. 8.6 crore loan assistance for chemical production facility
News | March 07, 2024

Govt supports Alchem Synthon with Rs. 8.6 crore loan assistance for chemical production facility

The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities


Strides receives USFDA approval for Gabapentin Tablets
Drug Approval | March 06, 2024

Strides receives USFDA approval for Gabapentin Tablets

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty


Dr. Mandaviya inaugurates Sadhana Nitro Chem’s Para Amino Phenol bulk drug plant
Policy | March 06, 2024

Dr. Mandaviya inaugurates Sadhana Nitro Chem’s Para Amino Phenol bulk drug plant

Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene


Bayer aims to enhance performance and regain strategic flexibility by 2026
News | March 06, 2024

Bayer aims to enhance performance and regain strategic flexibility by 2026

Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis


BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends
Diagnostic Center | March 06, 2024

BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months


Biocon Biologics secures Canada market entry date for YESAFILI
News | March 05, 2024

Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market